Healio Rheumatology Current Issue

The following articles appeared in the print edition of Healio Rheumatology.
Table of Contents
- ‘The art of medicine’: Physicians’ artistic pursuits strengthen empathy, sharpen skills Erich Martin
-
- Dementia more common in patients with RA receiving csDMARDs vs b/tsDMARDs Erich Martin
- Evolving COVID-19 variants limit effectiveness of current therapies Erich Martin
- ‘Huge surprise’: CAR-T cell therapy leads to remission in severe lupus Rob Volansky
- Large genome-wide study finds ‘dozens’ of new causal genes, pathways in gout Erich Martin
- Patients with IMIDs, myocardial infarction at higher risk for death, heart failure Erich Martin
- Ten-day MMF hiatus after COVID-19 vaccine doses boosts antibody response Robert Stott
- Understanding of long COVID shifting at ‘breakneck speed’ Rob Volansky
- Unvaccinated pregnant patients with RMDs, COVID-19 at higher risk for preterm birth Robert Stott
-
- Humanities and rheumatology: The time is now (again) Leonard H. Calabrese, DO
- ‘Can’t be in 10 places at once’: Social media now a key part of rheumatology meetings Erich Martin
- Hooked on Rheum with John R.P. Tesser, MD John R.P Tesser, MD
- Bone size, trabecular disorganization increase with osteophyte formation Erich Martin
- ACR: Continue daily monitoring in children with Kawasaki disease who have resolved fevers Erich Martin
- ‘Anatomy inventory’ fosters more inclusive care for transgender, non-binary patients Robert Stott
- Diet, exercise instruction improve knee osteoarthritis pain, function Erich Martin
- CATCR-T cell therapy may aid in antiphospholipid syndrome through selective B-cell depletion Erich Martin
-
- CMS proposes rule to streamline prior authorization, require justification for denials Erich Martin
- Denosumab achieves structural modification in erosive hand osteoarthritis Rob Volansky
- JAK inhibition’s cardiovascular, malignancy risks are a ‘moving target’ Rob Volansky